Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.49 |
| ▸ | SLC2A1 | P11166 | 3/20 | 0.47 |
| ▸ | HTR1A | P08908 | 2/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.46 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | FERMT2 | Q96AC1 | 1/20 | 0.42 |
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.42 |
| ▸ | CASP6 | P55212 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15826444 | 0.94 | S1PR2 (0.52) | LOXL2SLC2A1HTR1AADRA1DADRA1A | |
| Hydrochloric Acid SCHEMBL17260150 | 0.93 | SLC2A1 (0.52) | LOXL2SLC2A1HTR1AADRA1DADRA1A | |
| SCHEMBL1040581 | 0.83 | LOXL2 (0.55) | LOXL2HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL24197399 | 0.83 | LOXL2 (0.50) | LOXL2SLC2A1HTR1AADRA1DADRA1A | |
| SCHEMBL11935003 | 0.82 | LOXL2 (0.54) | LOXL2SLC2A1HTR1AADRA1DADRA1A | |
| SCHEMBL19563549 | 0.81 | HTR1A (0.53) | LOXL2HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL24197400 | 0.80 | GAA (0.50) | LOXL2SLC2A1HTR1AADRA1DADRA1A | |
| SCHEMBL30331546 | 0.80 | GAA (0.50) | LOXL2SLC2A1HTR1AADRA1DADRA1A | |
| SCHEMBL2448680 | 0.80 | HRH3 (0.57) | SLC2A1LMNASMN1; SMN2NPSR1KCNH2 | |
| SCHEMBL2237676 | 0.78 | LOXL2 (0.56) | LOXL2HTR1AADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012170175-A1 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, OR AMELIORATING INFLAMMATORY PAIN | BAUSCH & LOMB INCORPORATED (US) | 2012-12-13 | — | — | WO | disclosed |
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20120004262-A1 | PHENYLCYCLOPROPYLAMINE DERIVATIVES AND THEIR MEDICAL USE | ORYZON GENOMICS, S.A. (ES) | 2012-01-05 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004262-A1 | PHENYLCYCLOPROPYLAMINE DERIVATIVES AND THEIR MEDICAL USE | PNMT, ABCB1, SNCA | LOXL2 3999/4885SLC2A1 1019/4885HTR1A 71/4885 |
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | LOXL2 3899/4885SLC2A1 4225/4885HTR1A 1818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.